Translational Research
Epigenetic Signature – Case Study
Our senior advisor, Dr. Claudio Carini, led the translational medicine department at major pharmaceutical companies.
The Translational Medicine and Biomarkers Program Consultation will:
- Accelerate product development and approval.
- Increase the success of the clinical trials.
- Meet FDA and EMA high priority call for innovation in clinical research.
Case Study
Biomarker Signature in Rheumatoid Arthritis MTX Responders
PROJECT: One of the most important questions in treating physician’s mind is how to know which patient will respond to which drug in a given disease.
SOLUTION: Retrospective study in patients with early rheumatoid arthritis to identify a signature able to differentiate responder from no responder to methotrexate. Such a signature would allow for early treatment with biologics in patients not able to respond to first line treatment. Data showed the first signature able to predict responders from no-responders in RA patients. This work is a milestone in precision medicine for RA.
Results were published in J Transl Med. doi: [10.1186/s12967-018-1387-9]